The CD56 differentiation antigen, recognized by anti-Leu-19 and NKH-1 mAbs, is a 200-220-kD glycoprotein that is expressed predominantly on human NK cells and a minor subset ofT lymphocytes mediating MHC-unrestricted cytotoxicity (1-4).
were performed as described (10) . In indirect immunofluorescence, FITC-conjugated goat anti-mouse Ig (FGAM) antibody (Olympus, Tokyo, Japan) was used as the second antibody.
Cytotoxicity Assay. Cytotoxicity was measured using a standard 4 h 5'Cr release assay as described (10) .
Conjugate Formation Assay. Untreated or mAb-treated NK cells (106) and target cells (2 x 105) were mixed in a final volume of 100 1 .1 and centrifuged at 500 g for 1 min. After a 20-min incubation at room temperature, the cells were gently resuspended and counted under microscopy. NK cells and target cells were clearly discriminated by their distinctive difference in cell size. Target cells binding at least two NK cells were scored as positive and 200 target cells were counted in triplicate.
Results and Discussion
Recently, two antigen-independent pathways of effector-target cell binding have been demonstrated that are mediated by the interaction between CD2 on effector cells and LFA-3(CD58) on target cells, and by that between LFA-1 (CDlla/CD18) on effector cells and ICAM-1 (CD54) on target cells (11) . Relative contribution of either pathway to cell binding is variable among combinations ofeffector and target cells (11) . These two adhesion pathways are involved also in NK cell interaction with target cells (12) . To assess the putative adhesive function of CD56 on NK cells in a correlation with these known two pathways, we first examined the expression of CD56 among various target cells in parallel with those of LFA-3 and ICAM-1. Several tumor cell lines of neuroectodermal origin (U251MG and A172 glioblastomas, GOTO neuroblastoma, and G361 melanoma) were revealed to express CD56 as estimated by flow cytometry with NKH-1 mAb, although Molt-4 and K562 leukemia cell lines were CD56-(data not shown). This preferential expression of CD56 on neural tumor cell lines is consistent with the recent finding that CD56 is identical to N-CAM (5). Among them, we used a glioblastoma cell line U251MG (NKH-1', ICAM-1 -, LFA-3+) ( Fig. 1 ) and a T acute lymphoblastic leukemia (TALL) cell line Molt-4 (NKH-1 -, ICAM-1 +, LFA-3') ( Fig. 1) in the following studies, since they were highly susceptible for activated NK cells prepared by culturing low-buoyant density PBL with rIL-2 for 18 h.
We then examined the inhibitory effect of an anti-CD56 mAb (anti-Leu-19) on NK cell-mediated cytotoxicity against these two targets in conjunction with an anti-LFA-3 mAb (TS2/9) and/or an anti-LFA-1 mAb (25 .3) . Anti-LFA-3 mAb was preferred rather than anti-CD2 mAb to abrogate the CD2/LFA-3 interaction since anti-CD2 mAb may activate NK cell cytotoxicity in some circumstances (12) . Anti-LFA-1 mAb was also preferred rather than anti-ICAM-1 mAb since ICAM-1 is not the sole ligand for LFA-1 (13) . As shown in Fig . 2 , NK cell-mediated cytolysis against the CD56' target U251MG was only partially inhibited by anti-LFA-1 or anti-LFA-3 mAb alone and also by the combination of both anti-LFA-1 and anti-LFA-3 mAbs. In contrast, the cytotoxicity against the CD56-target Molt-4 was also partially blocked by anti-LFA-1 or anti-LFA-3 mAb alone, however, was completely abrogated by the combination ofboth anti-LFA-1 and anti-LFA-3 mAbs. Anti-Leu-19 mAb, when used alone, did not inhibit the NK cytotoxicity against U251MG and Molt-4. However, when used in combinations with anti-LFA-1 and/or anti-LFA-3 mAbs, anti-Leu-19 mAb did exhibit synergistic inhibitory effects, and a complete inhibition was attained only after the treatment with all the three mAbs, when CD56' U251MG was used as the target (Fig. 2) . No such synergistic inhibitory effect of anti-Leu-19 mAb was 0 observed when the CD56-Molt-4 was used as the target (Fig. 2) . A similar synergistic inhibitory effect with anti-LFA-1 and/or anti-LFA-3 mAbs was also observed when another anti-CD56 mAb, NKH-1, was used and when CD56+ GOTO, but not CD56-K562, were used as the targets (data not shown). These results indicate that CD56 on NK cells is involved in NK cell-mediated cytotoxicity when the target cells express CD56. We next examined the effect of anti-Leu-19 mAb on NK cell binding to CD56' or CD56 -target cells in conjunction with anti-LFA-1 and/or anti-LFA-3 mAbs. As shown in Fig. 3 , synergistic inhibitory effects of anti-Leu-19 mAb with anti-LFA-1 and/or anti-LFA-3 mAbs, similar to those observed in NK cell-mediated cytotoxicity (Fig. 2) , were observed again on NK cell binding to target cells only when FIGURE 2. Inhibitory effect of anti-Leu-19, anti-LFA-1, and/or anti-LFA-3 mAbs on NK cell-mediated cytotoxicity. Low-buoyant density PBL highly enriched for NK cells were cultured with 100 U/ml of rIL-2. After an 18-h culture, effector NK cells were preincubated with or without anti-Leu-19 mAb (10 pg/ml) and/or anti-LFA-1 mAb (25.3; 10 hg/ml) for 30 min at 37°C, and then cytotoxicity was tested against U251MG or Molt-4 target cells, which were preincubated with or without anti-LFA-3 mAb (TS2/9 ; 1 :100 dilution of ascites) for 30 min at 37°C, at an E/T ratio of 5:1 . It is evident from our data that CD56 on NK cells can function as an adhesion molecule, however, the physiological significance of the rather confined expression of N-CAM to NK cells and a minor subset ofT lymphocytes mediating MHC-unrestricted cytotoxicity in peripheral blood remains to be determined. Since N-CAM is expressed in various tissues (6) , the adhesive function of CD56 on the particular lymphocytes may be directly involved in their interaction with these tissues and cells expressing N-CAM . Further studies will be needed to test this possibility.
Summary
The CD56 differentiation antigen, recognized by anti-Leu-19 and NKH-1 mAbs, is a 200-220-kD glycoprotein that is expressed predominantly on human NK cells and a minor subset of T lymphocytes mediating MHC-unrestricted cytotoxicity. The recent finding that CD56 is an isoform of the neural cell adhesion molecule (N-CAM) prompted us to examine the adhesive function ofCD56 in the NK-target cell interaction . Synergistic inhibitory effects of anti-CD56 mAbs with anti-LFA-1 and/or anti-LFA-3 mAbs were demonstrated on NK cell-mediated cytotoxicity and on NK cell binding to target cells only when the target cells also express CD56. These findings indicate that CD56 on NK cells can serve as the third pathway of cell adhesion other than those mediated by the CD2/LFA-3 and LFA-1/ICAM-1 interactions, and is involved in NK cell cytotoxicity when interacting with the cells bearing N-CAM.
